It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Homologous recombination (HR) mediates the error-free repair of DNA double-strand breaks to maintain genomic stability. Here we characterize C17orf53/MCM8IP, an OB-fold containing protein that binds ssDNA, as a DNA repair factor involved in HR. MCM8IP-deficient cells exhibit HR defects, especially in long-tract gene conversion, occurring downstream of RAD51 loading, consistent with a role for MCM8IP in HR-dependent DNA synthesis. Moreover, loss of MCM8IP confers cellular sensitivity to crosslinking agents and PARP inhibition. Importantly, we report that MCM8IP directly associates with MCM8-9, a helicase complex mutated in primary ovarian insufficiency, and RPA1. We additionally show that the interactions of MCM8IP with MCM8-9 and RPA facilitate HR and promote replication fork progression and cellular viability in response to treatment with crosslinking agents. Mechanistically, MCM8IP stimulates the helicase activity of MCM8-9. Collectively, our work identifies MCM8IP as a key regulator of MCM8-9-dependent DNA synthesis during DNA recombination and replication.
Homologous recombination (HR) is an essential DNA repair pathway for genomic stability. Here the authors show that C17orf53/MCM8IP, an OB-fold containing protein, promotes HR through direct binding and activation of the MCM8-9 helicase complex.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Columbia University Irving Medical Center, Department of Genetics and Development, Herbert Irving Comprehensive Cancer Center, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
2 Università della Svizzera italiana, Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Bellinzona, Switzerland (GRID:grid.29078.34) (ISNI:0000 0001 2203 2861); ETH Zurich, Institute of Biochemistry, Department of Biology, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
3 University of Pittsburgh School of Medicine, Department of Microbiology and Molecular Genetics, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
4 Università della Svizzera italiana, Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Bellinzona, Switzerland (GRID:grid.29078.34) (ISNI:0000 0001 2203 2861)
5 Columbia University Irving Medical Center, Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
6 University of Utah, Department of Human Genetics, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)